Demand for Dario's integrated cardiometabolic solution
continues to grow as employers grappling with the surge in GLP-1
medication utilization search for proven ways to change health
behaviors
NEW
YORK, Nov. 27, 2023 /PRNewswire/
-- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the
"Company"), a leader in the global digital health market, announced
today a new contract to provide its cardiometabolic solution to an
employer (the "Employer") beginning in January 2024.
The Employer, a national financial and business services
company, selected Dario to improve the cardiometabolic health of
its population with an integrated solution for diabetes,
pre-diabetes, weight management and hypertension along with
tailored support for employees taking a GLP-1, or anti-obesity,
medications. Dario combines intelligent technologies and expert
human support to deliver highly personalized experiences using
insights from ten years of consumer engagement and is proven, in
prior studies, to provide sustainable improvements in clinical
outcomes.
"Dario is seeing increased interest in our proven ability to
help people achieve better cardiometabolic health through sustained
behavior change, a requirement for people using medications such as
GLP-1s. We are excited to support our new client's business goals
with effective and easy-to-use solutions which we believe employees
will love," said Rick Anderson,
President of Dario.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
https://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the expected timing of the launch of the solution,
the benefits that may be realized by members using Dario's
solutions, and the observed increased demand for Dario's integrated
cardiometabolic solution. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
Logo:
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
DarioHealth corporate contact:
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth investor relations contact:
Kat
Parella
Investor Relations Manager
+315-378-6922
Media contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
View original
content:https://www.prnewswire.com/news-releases/dario-contracts-with-new-employer-for-cardiometabolic-solution-301997872.html
SOURCE DarioHealth Corp.
